ABT-450/r/ABT-267, ABT-333
Sponsors
AbbVie (prior sponsor, Abbott), AbbVie
Conditions
Chronic Hepatitis CChronic Hepatitis C InfectionCompensated CirrhosisHepatitis C Virus
Phase 2
Phase 3
A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C
CompletedNCT01674725
Start: 2012-08-31End: 2014-10-31Updated: 2021-07-12
A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis
CompletedNCT01704755
Start: 2012-10-31End: 2014-09-30Updated: 2021-07-12
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
CompletedNCT01715415
Start: 2012-11-30End: 2014-10-31Updated: 2021-08-02
A Study to Evaluate Chronic Hepatitis C Infection
CompletedNCT01716585
Start: 2012-11-30End: 2014-10-31Updated: 2021-07-12
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
CompletedNCT01767116
Start: 2012-12-31End: 2014-08-31Updated: 2021-07-12
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
CompletedNCT01833533
Start: 2013-03-31End: 2014-09-30Updated: 2021-07-12
A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before
CompletedNCT01854697
Start: 2013-03-31End: 2015-07-31Updated: 2018-06-06
A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults
CompletedNCT01854528
Start: 2013-06-30End: 2015-07-31Updated: 2018-06-06